Literature DB >> 11576345

Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers.

K Amann1, A Koch, J Hofstetter, M L Gross, C Haas, S R Orth, H Ehmke, L C Rump, E Ritz.   

Abstract

BACKGROUND: Uremia is characterized by inadequately increased sympathetic activity. Sympathetic overactivity is involved in the genesis of hypertension in uremia, but its potential role on progression has not been well investigated. To address this issue, the effect of subantihypertensive doses of an alpha blocker and a beta blocker, and their combination on renal morphology and on albuminuria were investigated in the model of the subtotally nephrectomized rat.
METHODS: Male Sprague-Dawley rats were subjected to surgical ablation (SNX) or sham operation (sham). Three days after surgery groups were treated either with phenoxybenzamine (PBZ, 5 mg/kg body weight/day), metoprolol (MET, 150 mg/kg body weight/day) or their combination (PBZ 2.5 mg/kg body weight/day + MET, 50 mg/kg body weight/day). Renal morphology was evaluated after 12 weeks by quantitative histology, immunohistochemistry, and electron microscopy. Urine albumin excretion and kidney endothelin-1 (ET-1), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-beta) mRNA expression were assessed.
RESULTS: Systolic blood pressure was significantly higher in all SNX groups compared with sham-operated controls with no difference in the SNX groups. The number of glomeruli per left kidney was reduced from 30,904 +/- 3212 to 17,480 +/- 2341 by SNX (-43.5%). Mean glomerular volume increased from 2.63 +/- 0.7 in untreated sham operated to 4.11 +/- 0.48 microm 3 x 10(6) in untreated SNX (56.3%). The glomerulosclerosis index did not change in SNX + PBZ rats, but was significantly lower in SNX + MET (0.56 +/- 0.14) and particularly SNX + PBZ + MET rats (0.49 +/- 0.11) than in untreated SNX (0.74 +/- 0.24). Glomerular capillary length density (LV) as a sensitive index of capillary obliteration was significantly lower in SNX and almost normalized in the three intervention groups. The same was true for the mean podocyte number per glomerulus. Glomerular ultrastructure in SNX was largely preserved by all treatments. The albumin excretion rate was significantly higher in untreated SNX than in sham; it was significantly lower in all treated SNX groups.
CONCLUSION: The beneficial effect of non-hypotensive doses of alpha and beta blockers and their combination on renal morphology and albuminuria in the model of renal ablation argue for a blood pressure-independent role of sympathetic overactivity in the genesis of progression. In addition, the beneficial effect of adrenergic receptor blockade indicates that a substantial part is not mediated by sympathetic cotransmitters such as adenosine 5'-triphosphate (ATP) and neuropeptide Y (NPY).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576345     DOI: 10.1046/j.1523-1755.2001.00936.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  26 in total

1.  Alpha(2A)-adrenoceptors regulate sympathetic transmitter release in mice kidneys.

Authors:  O Vonend; S Habbel; J Stegbauer; J Roth; L Hein; L C Rump
Journal:  Br J Pharmacol       Date:  2006-11-20       Impact factor: 8.739

2.  Autonomic renal denervation ameliorates experimental glomerulonephritis.

Authors:  Roland Veelken; Eva-Maria Vogel; Karl Hilgers; Kerstin Amann; Andrea Hartner; Gabriele Sass; Winfried Neuhuber; Gisa Tiegs
Journal:  J Am Soc Nephrol       Date:  2008-04-09       Impact factor: 10.121

3.  Sympathetic nerves and the progression of chronic kidney disease during 5/6 nephrectomy: studies in sympathectomized rats.

Authors:  Robert A Augustyniak; Maria M Picken; David Leonard; Xin J Zhou; Weiguo Zhang; Ronald G Victor
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-06-29       Impact factor: 2.557

4.  Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease.

Authors:  Guido Grassi; Gino Seravalle; Lorenzo Ghiadoni; Giovanni Tripepi; Rosa Maria Bruno; Giuseppe Mancia; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-22       Impact factor: 8.237

5.  Long-Term Endothelin-A Receptor Antagonism Provides Robust Renal Protection in Humanized Sickle Cell Disease Mice.

Authors:  Malgorzata Kasztan; Brandon M Fox; Joshua S Speed; Carmen De Miguel; Eman Y Gohar; Tim M Townes; Abdullah Kutlar; Jennifer S Pollock; David M Pollock
Journal:  J Am Soc Nephrol       Date:  2017-03-27       Impact factor: 10.121

Review 6.  Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a Comprehensive Review.

Authors:  Ibrahim M Salman
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

7.  Nonhypotensive dose of beta-adrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure.

Authors:  Kerstin Amann; Jürgen Hofstetter; Valentina Câmpean; Andreas Koch; Marie-Luise Gross; Roland Veelken; Eberhard Ritz
Journal:  Virchows Arch       Date:  2006-05-12       Impact factor: 4.064

8.  Characterization of the renal phenotype in a mouse model of Marfan syndrome.

Authors:  Andrea Hartner; Timo Eifert; Christian S Haas; Cigdem Tuysuz; Karl F Hilgers; Dieter P Reinhardt; Kerstin Amann
Journal:  Virchows Arch       Date:  2004-07-29       Impact factor: 4.064

9.  Combined hydroxyurea and ETA receptor blockade reduces renal injury in the humanized sickle cell mouse.

Authors:  Crystal Taylor; Malgorzata Kasztan; Binli Tao; Jennifer S Pollock; David M Pollock
Journal:  Acta Physiol (Oxf)       Date:  2018-09-20       Impact factor: 6.311

Review 10.  Do beta-blockers combined with RAS inhibitors make sense after all to protect against renal injury?

Authors:  Eberhard Ritz; Lars Christian Rump
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.